Miostat
(Carbachol)Phase 2Small molecule
Miostat is one of 14 small molecule programs targeting Headache. It is currently in Phase 2.
2
Indications
5
Total Trials
0
Active Trials
13
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Presbyopia
#DrugCompanyPhaseTrials
1Bromday
BBausch Health Americas, Inc.
Approved
Alphagan
AbbViePhase 3
Alphagan
NovartisPhase 3
Isopto Carpine
AAdvanz Pharma
Phase 3
Pilocarpine Hcl
AbbViePhase 3
Miostat
FFalcon
Phase 2
Restasis
TTaiwan Bio Therapeutics Inc.
Phase 1
AGN-199201
AbbViePhase 2
AGN-190584
AbbViePhase 2
BAY 2701439
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Presbyopia3 trials
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
MIOSTAT
NDA NDA016968
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carbachol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]